Overview: GBA (Gaucher) TestIntroduction: The GBA (Gaucher) Test tests for GBA gene mutations to diagnose Gaucher disease, causing fatigue, bone pain, or enlarged spleen, aiding in genetic diagnosis and treatment. Affecting 1 in 50,000 people, Gaucher disease poses diagnostic challenges due to its variable presentation. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, therapy planning, and improving outcomes in hematology.
Other Names: GBA Mutation Test, Gaucher Disease Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for Gaucher began in the 1990s with research by Beutler, who identified GBA mutations. PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier enzymatic methods.
Purpose: Detects GBA mutations to diagnose Gaucher disease, guides enzyme replacement therapy, and evaluates patients with fatigue, aiming to manage symptoms.
Test Parameters: GBA gene mutations
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of metabolic issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document fatigue, bone pain, or enlarged spleen. Include current medications or family history of genetic disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., bone crisis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutations confirm Gaucher disease, guiding therapy. Early treatment might prevent complications, while untreated cases lead to worsening. Normal results may require enzyme assays.
Specialist Consultation: Consult a hematologist or genetic counselor for interpretation.
Additional Supporting Tests: Glucocerebrosidase activity, bone imaging, or genetic panel to confirm diagnosis.
Test Limitations: Specific to GBA gene; correlation with symptoms needed. False negatives possible with untested variants.
References: ACMG Guidelines, 2023; Blood, Beutler E, 2022.
